Followers | 7 |
Posts | 513 |
Boards Moderated | 0 |
Alias Born | 04/12/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 11, 2014 12:05:50 PM
"Meanwhile, Sanofi must hope a recent deal Mr. Viehbacher struck with MannKind Corp. to market the Afrezza inhaled insulin product will be a winner. Opinion is divided. Despite a crash-and-burn experience Pfizer Inc. suffered with such a product, supporters say Afrezza has a better delivery system and many diabetics don't like injectables.
Afrezza will be priced similarly to some injectable devices, but skeptics say diabetics will still have other options and payers must be convinced to give Afrezza preferential treatment for deciding reimbursement.
If the Afrezza deal sputters, one analyst says Sanofi may have to make a drastic decision.
“Sanofi will have to go big or go home,” says David Kliff of Diabetic Investor, who believes Sanofi should either acquire another company or diabetes portfolio. A prime candidate, in his view, is AstraZeneca PLC. “The simple fact is that Lilly and Novo have experience and formulary presence on their side.”
http://m.wsj.com/articles/sticking-point-sanofis-diabetes-franchise-is-crucial-to-sorting-out-a-mess-1415299834?mobile=y
In essence, as per the article, Sanofi is hoping and betting on its diabetic medications. It produces 21% of their revenue. At the moment some things have taken a turn with their top diabetic med and they need something to work out. Sanofi does not have as many products as the larger players and thus they are particularly banking on Afrezza to work out. Its a make or break. High risk high reward. Afrezza, IMO, if it works accordingly, will be pushed like a raging hot freight train by Sanofi to help restablize and then eventually break them into big player territory. They need Afrezza to work out. They dont have too many options.
Everything above is my opinion. I am NOT responsible for any influence I have on how you invest YOUR money; I INVEST MY MONEY and I am responsible for MY MONEY and that is it.
Recent MNKD News
- Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/05/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 01:00:03 AM
- MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix • GlobeNewswire Inc. • 05/29/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:00:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:09:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/21/2024 08:07:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2024 01:36:29 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM